Description

Technical Parameters

Introduction

raws

product-1400-1400

Products Description

### Systematic Analysis of Dapoxetine Raws Powder

Dapoxetine is a selective serotonin reuptake inhibitor (SSRI), mainly used to treat male premature ejaculation (PE). As a raw material (Raws Powder), its chemical purity, synthesis process and pharmacological properties directly affect the quality and efficacy of the final product. This article will systematically analyze Dapoxetine raw materials from six dimensions: chemical properties, pharmacological classification, production process, application field, market status and regulatory supervision.

#### 1. Chemical properties and classification

**1. Basic chemical information**

- **Chemical name**: (S)-N,N-dimethyl-3-(naphthalene-1-oxy)-1-phenylpropan-1-amine

- **CAS number**: 119356-77-3

- **Molecular formula**: C21H23NO

- **Molecular weight**: 305.41 g/mol

- **Appearance**: White to off-white crystalline powder

- **Solubility**: Slightly soluble in water, easily soluble in organic solvents (such as ethanol, chloroform).

**2. Structural classification and advantages**

Dapoxetine belongs to **amphetamine derivatives**, and its molecular structure contains a naphthalene ring and a chiral center (S configuration), which gives it the ability to bind to the 5-hydroxytryptamine transporter (SERT) with high selectivity.

- **Advantages**:

- **High purity**: The purity of the raw material is usually ≥99.5%, ensuring the stability of the preparation.

- **Optical activity**: Only the (S)-isomer has pharmacological activity, which needs to be achieved through asymmetric synthesis or chiral resolution.

- **Stability**: It can be stored for a long time under dry and light-proof conditions, with few degradation products.

**3. Classification of synthetic intermediates**

The synthesis of dapoxetine involves multiple steps, and the key intermediates include:

- **Intermediate A**: (S)-3-amino-3-phenylpropanol (CAS: 75606-85-0)

- **Intermediate B**: 1-naphthol (CAS: 90-15-3)

- **Intermediate C**: N,N-dimethylacrylamide (CAS: 2680-03-7)

#### 2. Pharmacological classification and mechanism of action

**1. Pharmacodynamic properties**

Dapoxetine inhibits the reuptake of 5-hydroxytryptamine and enhances the concentration of 5-HT in the synaptic cleft, thereby prolonging the ejaculation latency. Its features include:

- **Rapid onset**: Peak blood drug (Tmax) is reached 1-2 hours after oral administration, suitable for on-demand use.

- **Short half-life**: Elimination half-life is about 1.5 hours, reducing the risk of accumulation.

**2. Pharmacokinetic advantages**

- **Metabolic pathway**: Mainly metabolized by CYP3A4 and CYP2D6 enzymes to produce inactive products.

- **Dosage flexibility**: Two specifications of 30mg and 60mg, which can be adjusted according to patient response.

#### 3. Production process and technical route

**1. Mainstream synthesis route**

The industrial production of dapoxetine is mainly based on **asymmetric synthesis**, which is divided into the following steps:

1. **Construction of chiral center**: Using benzaldehyde as the starting material, the (S)-amino alcohol intermediate is generated by Strecker reaction.

2. **Naphthalene ring introduction**: 1-naphthol is connected to the amino alcohol skeleton through nucleophilic substitution reaction.

3. **Amine methylation**: Introduce N,N-dimethyl groups by Eschweiler-Clarke reaction.

**2. Process optimization direction**

- **Green chemistry**: Reduce the use of toxic reagents (such as cyanide) and use catalytic hydrogenation instead of traditional reduction process.

- **Continuous flow technology**: Improve reaction efficiency and reduce batch-to-batch differences.

#### 4. Application areas and formulation development

**1. Indication expansion**

In addition to premature ejaculation, dapoxetine is being studied in the following areas:

- **Female sexual dysfunction**: Preliminary studies have shown its potential efficacy for sexual arousal disorders.

- **Adjuvant treatment for depression**: Utilize its rapid 5-HT regulation properties.

**2. Dosage form innovation**

- **Orally disintegrating tablets**: Improve patient compliance and shorten the onset time to 30 minutes.

- **Long-acting microsphere injection**: For patients who need long-term treatment, extend the duration of action to 72 hours.

#### 5. Market status and competition landscape

**1. Global market size**

- **2023 valuation**: approximately US$1.5 billion, with a compound annual growth rate (CAGR) of 8.2% (2024-2030).

- **Regional distribution**: North America accounts for 45%, Europe 30%, and the Asia-Pacific region has the fastest growth (CAGR 12%).

**2. Major manufacturers**

- **Original research companies**: Johnson & Johnson (Janssen Pharmaceuticals) holds the patent until 2022.

- **API suppliers**:

- **India**: Sun Pharma, Dr. Reddy's (cost advantage, accounting for 60% of global supply).

- **China**: Huahai Pharmaceutical, Shijiazhuang Pharmaceutical Group (FDA certified, focusing on the high-end market).

#### 6. Regulations and quality control

**1. International Pharmacopoeia standards**

- **USP-NF**: stipulates that the total impurities of the relevant substances are ≤0.5%, and the single unknown impurity is ≤0.1%.

- **EP**: Chiral purity (S-isomer) ≥ 99.0%.

**2. Key test items**

- **HPLC method**: Determine the content of the main component and the impurity spectrum.

- **Chiral chromatography**: Ensure optical purity.

- **Residual solvent**: Comply with ICH Q3C guidelines (such as methanol ≤ 3000ppm).

#### 7. Future development trends

1. **Generic competition after patent expiration**: After 2022, global generic drug companies will accelerate their layout, and the demand for APIs will surge.

2. **New delivery system**: Development of non-first-pass effect dosage forms such as transdermal patches and nasal sprays.

3. **Combination therapy**: Combined with PDE5 inhibitors (such as sildenafil) to treat patients with comorbid ED and PE.

#### Conclusion

Dapoxetine API is the core substance for PE treatment, and its technical barriers are concentrated on chiral synthesis and impurity control. With the innovation of production technology and the expansion of indications, this product will continue to lead the development of men's health and bring rich returns to API companies. In the future, green synthesis technology and precise quality control will be the key battlefields of competition.